The Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed journal that publishes on all aspects of tumor immunology and cancer immunotherapy, aiming to enrich communication and advance scientific understanding in this rapidly evolving field. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.
New Oncolytic Virus-Based Treatment Effectively Treats Pancreatic Cancer💉🦠🔬
Researchers from Queen Mary University of London and Zhengzhou University have developed a powerful therapeutic platform that uses a modified Vaccinia virus (VV) for treating pancreatic cancer (PaCa). Pancreatic cancer is the seventh leading cause of cancer death worldwide, which also has the lowest survival rate of all the common cancers, with less than 7% of patients surviving for five years or more.